Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints.
While previous results of genetic association studies for common, complex diseases (eg., coronary artery disease, CAD) have been disappointing, examination of multiple related genes within a physiologic pathway may provide improved resolution. This paper describes a method of calculating a genetic risk score (GRS) for a clinical endpoint by integrating data from many candidate genes and multiple intermediate phenotypes (IPs). First, the association of all single nucleotide polymorphisms (SNPs) to an IP is determined and regression beta-coefficients are used to calculate an IP-specific GRS for each individual, repeating this analysis for every IP. Next, the IPs are assessed by a second regression as predictors of the clinical endpoint. Each IP's individual GRS is then weighted by the regression beta-coefficients from the second step, creating a single, composite GRS. As an example, 3,172 patients undergoing coronary angiography were evaluated for 3 SNPs from the cholesterol metabolism pathway. Although these data provide only a preliminary example, the GRS method detected significant differences in CAD by GRS group, whereas separate genotypes did not. These results illustrate the potential of the GRS methodology for multigenic risk evaluation and suggest that such approaches deserve further examination in common, complex diseases such as CAD.
Horne
B D
BD
Cardiovascular Department, LDS Hospital, Intermountain Health Care, 8th Avenue and C Street, Salt Lake City, UT 84143, USA. benjamin.horne@ihc.com
Anderson
J L
JL
Carlquist
J F
JF
Muhlestein
J B
JB
Renlund
D G
DG
Bair
T L
TL
Pearson
R R
RR
Camp
N J
NJ
D003327:Coronary Disease / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D018570:Risk Assessment
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):815-22
10712408
Circulation. 1995 Apr 15;91(8):2120-4
7697839
Ann Hum Genet. 2002 Mar;66(Pt 2):111-24
12174215
Science. 1997 Nov 28;278(5343):1580-1
9411782
Nature. 2000 Jun 15;405(6788):847-56
10866211
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):481-8
11304461
Am J Med. 2002 Jun 3;112 Suppl 8A:10S-18S
12049990
Genet Epidemiol. 2004 Jan;26(1):11-21
14691953
Circulation. 2000 Oct 31;102(18):2197-203
11056092
Am J Hum Genet. 2001 Jul;69(1):138-47
11404819
Am Heart J. 2000 Oct;140(4):S11-26
11011311
Am Heart J. 2002 Dec;144(6 Suppl):S33-42
12486414
N Engl J Med. 1998 Jan 8;338(2):86-93
9420339
J Lipid Res. 2001 Nov;42(11):1717-26
11714841
Nat Genet. 1999 May;22(1):1-2
10319845
Atherosclerosis. 2003 Feb;166(2):285-90
12535741
J Am Coll Cardiol. 2003 Jun 4;41(11):1972-82
12798568
Am J Cardiol. 2005 Jan 1;95(1):155-8
15619419
Circulation. 2000 Apr 25;101(16):1907-12
10779455
Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):1969-76
11742872
Science. 1996 Sep 13;273(5281):1516-7
8801636
Am J Hum Genet. 1984 Jul;36(4):836-57
6591796
Science. 1996 Oct 25;274(5287):536-9
8928008
N Engl J Med. 1984 Mar 22;310(12):750-8
6608052
J Am Coll Cardiol. 1998 Mar 15;31(4):790-6
9525548
J Cardiovasc Risk. 2002 Apr;9(2):105-13
12006918
Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):971-8
11397706
Lancet. 2000 Feb 5;355(9202):434-42
10841123
Circulation. 2001 Feb 13;103(6):792-8
11171785
Nat Genet. 2002 May;31(1):33-6
11984562
Nat Genet. 2001 Oct;29(2):233-7
11586306
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1323-9
10807749